- Home
-
Technical Platform
-
Services
- TCR-T Lead Sequence Development Service
- Immune CAR Cell Preparation Technology Service
- Antibody Coupled Drug Discovery Service
- Antibody Affinity Maturation Service
- Antibody Humanization Services
- Bispecific Antibody Development Services
- Antibody Protein Sequencing Service
- Antibody Affinity Determination Service
Antibody Drugability Assessment
- Aptamer-Drug Conjugate (ApDC) Development Services
- Nuclide Nucleic Acid Aptamer Screening Service
- Nucleic Acid Aptamer Synthesis Service
- Nucleic Acid Aptamer Modification Service
- Nucleic Acid Aptamer Library Construction Service
- Bispecific Aptamer Development Service
- Protein Nucleic Acid Aptamer Screening Service
- Metal Ion Nucleic Acid Aptamer Screening Service
- Small Molecule Nucleic Acid Aptamer Screening Service
- Cell Nucleic Acid Aptamer Screening Service
- Peptide Affinity Maturation Services
- Peptide-Drug Conjugate (PDC) Development Services
- Stapled Peptide Development Services
- Targeted Peptide Library Screening Service
- Targeted Peptide Library Construction Service
Active Peptide Discovery Technology Service
- mRNA Antibody Production Services
- mRNA Immunogen Production Service
- DNA Immune Antibody Preparation Service
Animal Immunization Technology Services
- Yeast Two-hybrid (Nuclear System) Service
- Yeast Two-hybrid (Membrane System) Service
- Yeast cDNA Library Construction Technology Service
- Yeast One Hybrid Service
Yeast Hybrid Technology Platform
- Recombinant Chimeric Antibodies Customized Services
- Recombinant IgG Customization Services
- Recombinant Fragment Antibody Customization Service
Recombinant Antibody Expression Services
-
Technical Support
- Nanobodies: How a 15 kDa Single-Domain Antibody Breaks Through the Limits of Conventional Therapy
- Structural Basis for Selectivity and Antagonism in GPCR-Nanobodies
- Novel Peptide-Drug Conjugate (PDC) Shows Efficacy in Hepatocellular Carcinoma Models
- Nanobody Expression in Insect Cells
- Nanobody Mammalian Cell Expression
- Single-chain Antibody Library Construction Technology Introduction
- Prokaryotic Expression of Nanobodies
- Cell Line Immunogen of Nanobody
- Construction of Single Chain Antibody Library
- Nano-antibody/Single Domain Antibody Library Construction Service
- Recombinant Expression Strategies for Bispecific Antibodies: What You Need to Know？
- Antibody Engineering and Modification: Maximizing Therapeutic and Diagnostic Utility
- Bispecific Antibodies (bsAbs): Mechanisms of Action Explained
- Applications of bispecific antibodies in cancer therapy
- Beyond PD-1 Blockade: How BiCE Bridges T Cells and cDC1s to Unlock Cold Tumors
- From Purity to Functionality: A Comprehensive Guide to Recombinant Antibody Quality Control Standards
- How much do you know about the molecular design and mechanism of action of ADC drugs?
- The ADC linker serves as a crucial "bridge" component.
- ADCs are becoming increasingly mature in the field of tumor therapy.
- Cracking the Immune System’s “Source Code”: Why Is B-Cell Technology the Ultimate Path to Antibody Discovery?
Special topic on antibody modification
- After the Halo Fades: How Antibody Discovery Is Returning to Science — and to Systems
- From Cell Line to Purified Drug Substance: How Therapeutic Antibodies Are Manufactured in Mammalian Cells
- High-Throughput Yeast Display Platform for Macrocyclic Peptide Discovery
- How Are Antibody Drugs Produced? A Deep Dive into Mammalian Cell Culture and Purification Processes
- Expression of Recombinant Antibodies in Mammalian Cells: Core Technologies – Comprehensive Analysis of Host Selection and Purification Strategies
- Bacteriophages, yeast, mRNA display: Who is the champion of the display technology?
- Breakthrough: Ultra-High Sensitivity Detection of Legionella Using an Aptamer-Based Electrochemical Sensor
- Construction of yeast hybrid library: Gateway technology
- Eukaryotic System-Based Targeted Drug Discovery Platform: Yeast Display Technology
- Common Problems and Solutions for Yeast Two-hybrid Experiments
Yeast Display Technology Special Topic
- Empowering Precision Medicine: The "Magic Scissors" and "Master Strokes" of Antibody Engineering
- Humanization calculation method and structural feature analysis of nanobodies！
- Stop Sticking with Hybridoma! A Primer on the Three Generations of Antibody Discovery Technology
- Rationale and Significance of Bispecific Antibody Development
- Protein Not Expressing? You Might Have Chosen the Wrong Tag!
- What to Do After Protein Purification? These Four Validation Methods You Must Know!
- Yeast Two-Hybrid Technology Reveals a Novel Mechanism of Wheat Disease Resistance: How TaPIR1 "Hijacks" TaHRP1 to Suppress Chloroplast Function?
- Yeast Hybrid Library Construction: Smart Technology
- New Molecular Interaction Technology: How Much Do You Know About Yeast Hybridization Technology?
- Antibody Affinity Testing(SPR)
Antibody Detection Service Topic
- Peptide-Targeted Nanoparticles for Tumor Therapy: Vascular Homing Peptides Review
- Frontiers in Targeted Drug Development: Comparison and Application of Various Peptide Screening Methods
- Application of phage display (Part 2)
- Application of phage display (Part 1)
- Phage Display
- Technical Article: Detailed Guide to Phage Screening
- Frontiers in Targeted Drug Development: Comparison and Application of Multiple Peptide Screening Methods
- Revolutionary Advances in Single-Domain Antibody Development and Applications
- New Method for Discovering Targeted Drugs: Screening of Peptide Libraries Based on Phage Display Technology
- How much do you know about IgG, Fab, scFv, and VHH?
Special Topic on Phage Display Technology
- CD7-targeted Antibody-Drug Conjugates: A New Hope for T-Cell Acute Lymphoblastic Leukemia
- Discovery of targeted nucleic acid small molecules: Cell-SELEX technology
- A Promising Novel Cancer Therapeutic Strategy: Aptamer-Drug Conjugates (ApDCs)
- A Novel Therapeutic Approach for Multiple Myeloma: Development of a CD38 and CD47 Bispecific Bipartopic Antibody
- A Novel Therapeutic Approach - CAR-M
- Application And Prospects of CAR-T Technology in Tumor Immunotherapy
- CAR-T Discovery Service
CAR-T Molecule Discovery Topic
- Stop Screening Aptamers the Old Way: The Decisive Advantage of Magnetic-Bead SELEX
- Magnetic Beads: How Do They Make SELEX Technology Fast, Precise, and Reliable?
- Screening and optimization of nucleic acid aptamers
- Main Research Directions Progress and Challenges of Nucleic Acid Aptamer Screening Technology
- Research Progress of Protein Nucleic Acid Aptamer Screening
- Nucleic Acid Aptamer Libraries Screening: an Efficient Method for Discovering Specific Binding Molecules
Special topic on adapter development
- In Vivo Screening Services – Animal Models
- The Promise of Small Nucleic Acid Therapeutics: From Bench to Clinic as Next-Generation Medicines
- Issues Related to Aptamer Library Screening
- Introduction to Nucleic Acid Aptamer Library Screening Technology
- Screening and Application of Peptide Aptamers
- Research Progress of Aptamer Screening-of Small Molecule Targets
Molecular Biology Service Topics
-
Product Center
- Contact Us
Bispecific aptamers bind two targets with one molecule, overcoming tumor heterogeneity and drug resistance. Explore rational design strategies from TekBiotech.
Over 70% of recent aptamer papers use magnetic beads. Here is why bead-based SELEX outperforms membrane SELEX — and how to design negative selection right.
Why therapeutic antibody discovery is shifting from animal immunization to standardized phage and yeast display platforms — and how to choose between them.
Nanobodies are 15 kDa single-domain antibodies (VHH) that improve tissue penetration and stability. Explore nanobody discovery strategies and engineering for therapy.\n
pH-dependent antibodies extend half-life while accelerating target clearance. Learn the acid-switch mechanism, engineering strategies, and the Fc–FcRn affinity threshold.
Magnetic bead–based SELEX (MB-SELEX) offers far more than convenient separation—it makes negative and competitive selection programmable. \n
This article reviews the key antibody engineering and chemical modification strategies that overcome these limitations, including humanized and fully human antibodies, antibody fragments and miniaturization , antibody–drug conjugates (ADCs), PEGylation.
Nanobody humanization is a key strategy for reducing the immunogenicity of camelid-derived VHH candidates and improving their compatibility with the human immune system.
Therapeutic antibodies have become household names — from PD-1 inhibitors that fight cancer to TNF-α antagonists that treat autoimmune diseases. Almost all of them depend on a shared "factory": the mammalian cell.
Affibody molecules are 6.5 kDa engineered affinity proteins for molecular imaging and targeted therapy. Taike Biotech provides phage display, screening, and one-stop development services.\n
